Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Steve Cohen’s SAC Capital in SEC Cougar Probe

The SEC is not done with Steve Cohen nor Raj Rajaratnam reports BusinessInsider. It has launched a probe into the activities of several hedge funds regarding the takeover of Cougar Biotechnology, including Rajaratnam’s Galleon Group and Steve Cohen’s SAC Capital. Cougar is a biopharmaceutical company that focuses primarily on oncology.  Specifically, in 2009, Cougar was developing various compounds to aid in the treatment of different cancers, including prostate cancer, breast cancer and myeloma. Johnson & Johnson (JNJ) bought the company on May 21, 2009 for $1 billion – the deal sent shares in Cougar soaring 16%.


SEC Cougar Takeover Investigation, Starring Steve Cohen, Raj Rajaratnam and Stanley Druckenmiller, Amongst Others

Now here is where it gets interesting. The SEC is raising questions about Steve Cohen’s SAC Capital Management‘s ownership of Cougar shares before the deal and its relationship with MedaCorp, the investment bank that advised Cougar through the buyout process. According to the Wall Street Journal, “Regulators also have examined trading around the Cougar takeover by other hedge funds, including Stanley Druckenmiller‘s Duquesne Capital Management and [Raj Rajaratnam’s] Galleon Group. It is unclear whether the examinations are continuing.” The Wall Street Journal also clarifies, “The SEC hasn’t accused SAC or the other entities involved in the Cougar probe of wrongdoing. It is unclear whether the inquiries, which have been ongoing for more than a year, will result in any charges.”

SEC vs SAC, Round Three

This is just one of the investigations that are currently ongoing that involve SAC Capital. In June, the Wall Street Journal reported that the SEC was looking into whether SAC used inside information to benefit from the 2007 takeover of MedImmune Inc. The SEC never levied any charges in the matter. The SEC is also looking into SAC Capital’s practices as part of a criminal probe regarding “trades made in an account overseen by the fund’s billionaire founder, Steven A. Cohen, according to court documents and people familiar with the matter,” reports the Wall Street Journal.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!